Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.24.86 extracted from

  • Wang, Y.; Wu, J.; Newton, R.; Bahaie, N.; Long, C.; Walcheck, B.
    ADAM17 cleaves CD16b (FcgammaRIIIb) in human neutrophils (2013), Biochim. Biophys. Acta, 1833, 680-685.
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.24.86

Application

Application Comment Organism
medicine human IgG Fc receptor CD16, i.e. FcgammaRIII plasma levels are significantly decreased in patients administered a selective inhibitor targeting the metalloproteases ADAM10 and ADAM17. Inhibition of ADAM17 significantly blocks the cleavage of CD16b following neutrophil activation and apoptosis Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazin-1-ylcarbonyl)-5-azaspiro[2.5]octane-5-carboxylate i.e. INCB7839, selective inhibitor of endopeptidases ADAM-10 and ADAM-17 Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P78536
-
-

Source Tissue

Source Tissue Comment Organism Textmining
neutrophil
-
 Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
CD16b + H2O human IgG Fc receptor CD16, i.e. FcgammaRIII. CD16b plasma levels are significantly decreased in patients administered a selective inhibitor targeting the metalloproteases ADAM10 and ADAM17. Inhibition of ADAM17 significantly blocks the cleavage of CD16b following neutrophil activation and apoptosis Homo sapiens ?
-
 ?